首页    期刊浏览 2025年06月09日 星期一
登录注册

文章基本信息

  • 标题:Imidapril, an Angiotensin-Converting Enzyme Inhibitor, Inhibits Thrombosis via Reduction in Aortic Plasminogen Activator Inhibitor Type-1 Levels in Spontaneously Hypertensive Rats
  • 本地全文:下载
  • 作者:Takashi MITSUI ; Susumu CHISHIMA ; Akio ODAWARA
  • 期刊名称:Biological and Pharmaceutical Bulletin
  • 印刷版ISSN:0918-6158
  • 电子版ISSN:1347-5215
  • 出版年度:1999
  • 卷号:22
  • 期号:8
  • 页码:863-865
  • DOI:10.1248/bpb.22.863
  • 出版社:The Pharmaceutical Society of Japan
  • 摘要:It is known that angiotensin II (Ang II) exerts an antifibrinolytic effect by stimulating synthesis of plasminogen activator inhibitor type-1 (PAI-1), a specific inhibitor of tissue plasminogen activator (t-PA). The aim of this study was to compare the antithrombotic potency of imidapril, an angiotensin-converting enzyme (ACE) inhibitor, and candesartan, an angiotensin II type 1 (AT1) receptor antagonist, in a model of arterial thromboss in spontaneously hypertensive rats (SHRs).Oral treatment with 5 mg/kg imidapril 1 h before induction of thrombosis resulted in a significant reduction in thrombus weight, whereas candesartan did not affect thrombus weight the same treatment conditions. Candesartan lowered blood pressure to the same degree as in the imidapril-treated rats. Imidapril not only reduce the serum and aortic ACE activities, but also reduced aortic PAI-1 protein levels, while candesartan had no effect on theses.These results suggest that imidapril, but not the AT1 receptor antagonist, candesartan, enhances fibrinolysis via a reduction of aortic PAI-1 levels by inhibiting ACE and prevents thrombus formation in SHRs.
国家哲学社会科学文献中心版权所有